Search

Your search keyword '"Stuve, Olaf"' showing total 440 results
Start Over Author "Stuve, Olaf"
440 results on '"Stuve, Olaf"'

1. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Author

Montalban, Xavier, Vermersch, Patrick, Arnold, Douglas L, Bar-Or, Amit, Cree, Bruce A C, Cross, Anne H, Kubala Havrdova, Eva, Kappos, Ludwig, Stuve, Olaf, Wiendl, Heinz, Wolinsky, Jerry S, Dahlke, Frank, Le Bolay, Claire, Shen Loo, Li, Gopalakrishnan, Sathej, Hyvert, Yann, Javor, Andrija, Guehring, Hans, Tenenbaum, Nadia, and Tomic, Davorka

Published
2024
Full Text
View/download PDF

7. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Author

Jia, Xiaoming, Madireddy, Lohith, Caillier, Stacy, Santaniello, Adam, Esposito, Federica, Comi, Giancarlo, Stuve, Olaf, Zhou, Yuan, Taylor, Bruce, Kilpatrick, Trevor, Martinelli-Boneschi, Filippo, Cree, Bruce AC, Oksenberg, Jorge R, Hauser, Stephen L, and Baranzini, Sergio E

Subjects
Humans, Cysts, Multiple Sclerosis, Chronic Progressive, Hereditary Central Nervous System Demyelinating Diseases, Paraplegia, Kinesin, Membrane Transport Proteins, Membrane Proteins, Cohort Studies, Genotype, Phenotype, Mutation, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Female, Male, Meta-Analysis as Topic, Genome-Wide Association Study, Young Adult, Clinical Sciences, Neurosciences, Neurology & Neurosurgery
Abstract

ObjectivePrimary progressive multiple sclerosis (PPMS) causes accumulation of neurological disability from disease onset without clinical attacks typical of relapsing multiple sclerosis (RMS). However, whether genetic variation influences the disease course remains unclear. We aimed to determine whether mutations causative of neurological disorders that share features with multiple sclerosis (MS) contribute to risk for developing PPMS.MethodsWe examined whole-genome sequencing (WGS) data from 38 PPMS and 81 healthy subjects of European ancestry. We selected pathogenic variants exclusively found in PPMS patients that cause monogenic neurological disorders and performed two rounds of replication genotyping in 746 PPMS, 3,049 RMS, and 1,000 healthy subjects. To refine our findings, we examined the burden of rare, potentially pathogenic mutations in 41 genes that cause hereditary spastic paraplegias (HSPs) in PPMS (n = 314), secondary progressive multiple sclerosis (SPMS; n = 587), RMS (n = 2,248), and healthy subjects (n = 987) genotyped using the MS replication chip.ResultsWGS and replication studies identified three pathogenic variants in PPMS patients that cause neurological disorders sharing features with MS: KIF5A p.Ala361Val in spastic paraplegia 10; MLC1 p.Pro92Ser in megalencephalic leukodystrophy with subcortical cysts, and REEP1 c.606 + 43G>T in Spastic Paraplegia 31. Moreover, we detected a significant enrichment of HSP-related mutations in PPMS patients compared to controls (risk ratio [RR] = 1.95; 95% confidence interval [CI], 1.27-2.98; p = 0.002), as well as in SPMS patients compared to controls (RR = 1.57; 95% CI, 1.18-2.10; p = 0.002). Importantly, this enrichment was not detected in RMS.InterpretationThis study provides evidence to support the hypothesis that rare Mendelian genetic variants contribute to the risk for developing progressive forms of MS. Ann Neurol 2018;83:51-63.

Published
2018

10. Toward Precision Phenotyping of Multiple Sclerosis

Author

Pitt, David, Lo, Chih Hung, Gauthier, Susan A., Hickman, Richard A., Longbrake, Erin, Airas, Laura M., Mao-Draayer, Yang, Riley, Claire, De Jager, Philip Lawrence, Wesley, Sarah, Boster, Aaron, Topalli, Ilir, Bagnato, Francesca, Mansoor, Mohammad, Stuve, Olaf, Kister, Ilya, Pelletier, Daniel, Stathopoulos, Panos, Dutta, Ranjan, and Lincoln, Matthew R.

Published
2022
Full Text
View/download PDF

14. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Author

Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Becher, Burkhard, Bethoux, François, Brandt, Alexander, Brownlee, Wallace, Calabresi, Peter, Chatway, Jeremy, Chien, Claudia, Chitnis, Tanuja, Ciccarelli, Olga, Cohen, Jeffrey, Comi, Giancarlo, Correale, Jorge, De Sèze, Jerome, De Stefano, Nicola, Fazekas, Franz, Flanagan, Eoin, Freedman, Mark, Fujihara, Kazuo, Galetta, Steven, Goldman, Myla, Greenberg, Benjamin, Hartung, Hans-Peter, Hemmer, Bernhard, Henning, Anke, Izbudak, Izlem, Kappos, Ludwig, Lassmann, Hans, Laule, Cornelia, Levy, Michael, Lublin, Fred, Lucchinetti, Claudia, Lukas, Carsten, Marrie, Ruth Ann, Miller, Aaron, Miller, David, Montalban, Xavier, Mowry, Ellen, Ourselin, Sebastien, Paul, Friedemann, Pelletier, Daniel, Ranjeva, Jean-Philippe, Reich, Daniel, Reingold, Stephen, Rocca, Maria Assunta, Rovira, Alex, Schlaerger, Regina, Soelberg Sorensen, Per, Sormani, Maria, Stuve, Olaf, Thompson, Alan, Tintoré, Mar, Traboulsee, Anthony, Trapp, Bruce, Trojano, Maria, Uitdehaag, Bernard, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian, Wheeler-Kingshott, Claudia Gandini, Xu, Junqian, Cohen, Jeffrey A, Reingold, Stephen C, and Weinshenker, Brian G

Published
2019
Full Text
View/download PDF

16. Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design.

Author

Sguigna, Peter V., Hussain, Rehana Z., Okai, Annette, Blackburn, Kyle M., Tardo, Lauren, Madinawala, Mariam, Korich, Julie, Lebson, Lori A., Kaplan, Jeffrey, Salter, Amber, Manouchehri, Navid, and Stuve, Olaf

Subjects
ANTINEOPLASTIC agents, NATALIZUMAB, MULTIPLE sclerosis, DRUG efficacy, DRUG side effects
Abstract

Background: Individual disease modifying therapies approved for multiple sclerosis (MS) have limited effectiveness and potentially serious side effects, especially when administered over long periods. Sequential combination therapy is a plausible alternative approach. Natalizumab is a monoclonal therapeutic antibody that reduces leukocyte access to the central nervous system that is associated with an increased risk of progressive multifocal leukoencephalopathy and disease reactivation after its discontinuation. Cladribine tablets act as a synthetic adenosine analog, disrupting DNA synthesis and repair, thereby reducing the number of lymphocytes. The generation of prospective, rigorous safety, and efficacy data in transitioning from natalizumab to cladribine is an unmet clinical need. Objectives: To test the feasibility of transitioning patients with relapsing forms of MS natalizumab to cladribine tablets. Design: Cladribine tablets after treatment with natalizumab (CLADRINA) is an open-label, single-arm, multicenter, collaborative phase IV, research study that will generate hypothesis regarding the safety, efficacy, and immunological impact of transition from natalizumab to cladribine tablets in patients with relapsing forms of MS. Methods and analysis: Participants will be recruited from three different sites. The primary endpoint is the absolute and percent change from baseline of lymphocytes and myeloid cell subsets, as well as blood neurofilament light levels. The secondary endpoint is the annualized relapse rate over the 12- and 24-month trial periods. Exploratory endpoints include the expanded disability status scale, and magnetic resonance imaging outcomes. Discussion: The CLADRINA trial will generate data regarding the safety, efficacy, and immunological impact of the transition from natalizumab to cladribine. As the pace of immunological knowledge of MS continues, insight into disease modifying therapy transition strategies is needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Author

Achiron, Anat, Achtnichts, Lutz, Agan, Kadriye, Akman-Demir, Gulsen, Allen, Alison B, Antel, Jack P, Antiguedad, Alfredo Rodriguez, Apperson, Michelle, Applebee, Angela M, Ayuso, Guillermo Izquierdo, Baba, Masayuki, Bajenaru, Ovidiu, Balasa, Rodica, Balci, Belgin Petek, Barnett, Michael, Bass, Ann, Becker, Veit U, Bejinariu, Mihaela, Bergh, Florian Then, Bergmann, Arnfin, Bernitsas, Evanthia, Berthele, Achim, Bhan, Virender, Bischof, Felix, Bjork, Randall John, Blevins, Gregg, Boehringer, Matthias, Boerner, Thomas, Bonek, Robert, Bowen, James D, Bowling, Allen, Boyko, Alexey N, Boz, Cavit, Bracknies, Vera, Braune, Stefan, Brescia Morra, Vincenzo, Brochet, Bruno, Brola, Waldemar, Brownstone, Paul Kenneth, Brozman, Miroslav, Brunet, Donald, Buraga, Ioan, Burnett, Margaret, Buttmann, Mathias, Butzkueven, Helmut, Cahill, Jonathan, Calkwood, Jonathan C, Camu, William, Cascione, Mark, Castelnovo, Giovani, Centonze, Diego, Cerqueira, Joao, Chan, Andrew, Cimprichova, Andrea, Cohan, Stanley, Comi, Giancarlo, Conway, Jill, Cooper, Joanna A, Corboy, John, Correale, Jorge, Costell, Brian, Cottrell, David A, Coyle, Patricia K, Craner, Matthew, Cui, Liying, Cunha, Luis, Czlonkowska, Anna, da Silva, Ana Martins, de Sa, Joao, de Seze, Jérôme, Debouverie, Marc, Debruyne, Jan, Decoo, Danny, Defer, Gilles, Derfuss, Tobias, Deri, Norma H, Dihenia, Bhupesh, Dioszeghy, Peter, Donath, Vladimir, Dubois, Benedicte, Duddy, Martin, Duquette, Pierre, Edan, Gilles, Efendi, Husnu, Elias, Stanton, Emrich, Peter J, Estruch, Bonaventura Casanova, Evdoshenko, Evgeniy P, Faiss, Juergen, Fedyanin, Alexander S, Feneberg, Wolfgang, Fermont, Jiske, Fernandez, Oscar Fernandez, Ferrer, Francisco Coret, Fink, Katharina, Ford, Helen, Ford, Corey, Francia, Ada, Freedman, Mark, Frishberg, Benjamin, Galgani, Simonetta, Garmany, George P, Gehring, Klaus, Gitt, Jeffrey, Gobbi, Claudio, Goldstick, Lawrence P, Gonzalez, Rafael Arroyo, Grandmaison, Francois, Grigoriadis, Nikolaos, Grigorova, Olga, Grimaldi, Luigi Maria Edoardo, Gross, Jeffrey, Gross-Paju, Katrin, Gudesblatt, Mark, Guillaume, Daniel, Haas, Judith, Hancinova, Viera, Hancu, Anca, Hardiman, Orla, Harmjanz, Arndt, Heidenreich, Fedor R, Hengstman, G J D, Herbert, Joseph, Herring, Mark, Hodgkinson, Suzanne, Hoffmann, Olaf M, Hofmann, Werner E, Honeycutt, William D, Hua, Le Hanh, Huang, Dehui, Huang, Yining, Huang, DeRen, Hupperts, Raymond, Imre, Piroska, Jacobs, Alan Keith, Jakab, Gabor, Jasinska, Elzbieta, Kaida, Kenichi, Kalnina, Jolanta, Kaprelyan, Ara, Karelis, Guntis, Karussis, Dimitrios, Katz, Amos, Khabirov, Farit A, Khatri, Bhupendra, Kimura, Takashi, Kister, Ilya, Kizlaitiene, Rasa, Klimova, Eleonora, Koehler, Juergen, Komatineni, Aparna, Kornhuber, Anselm, Kovacs, Krisztina, Koves, Agnes, Kozubski, Wojciech, Krastev, Georgi, Krupp, Lauren B, Kurca, Egon, Lassek, Christoph, Laureys, Guy, Lee, Liesly, Lensch, Eckart, Leutmezer, Fritz, Li, Hongzeng, Linker, Ralf A, Linnebank, Michael, Liskova, Petra, Llanera, Cristina, Lu, Jiahong, Lutterotti, Andreas, Lycke, Jan, Macdonell, Richard, Maciejowski, Maciej, Maeurer, Mathias, Magzhanov, Rim V, Maida, Eva-Maria, Malciene, Lina, Mao-Draayer, Yang, Marfia, Girolama Alessandra, Markowitz, Clyde, Mastorodimos, Vasileios, Matyas, Klotild, Meca-Lallana, Jose, Merino, Juan Antonio Garcia, Mihetiu, Ioan Gheorghe, Milanov, Ivan, Miller, Aaron E, Millers, Andrejs, Mirabella, Massimiliano, Mizuno, Masanori, Montalban, Xavier, Montoya, Lilina, Mori, Masahiro, Mueller, Stefanie, Nakahara, Jin, Nakatsuji, Yuji, Newsome, Scott, Nicholas, Richard, Nielsen, A Scott, Nikfekr, Esmaeil, Nocentini, Ugo, Nohara, Chiyoko, Nomura, Kyoichi, Odinak, Miroslav M, Olsson, Tomas, van Oosten, B W, Oreja-Guevara, Celia, Oschmann, Patrick, Overell, James, Pachner, Andrew, Panczel, Gyula, Pandolfo, Massimo, Papeix, Caroline, Patrucco, Liliana, Pelletier, Jean, Piedrabuena, Raul, Pless, Misha, Polzer, Udo, Pozsegovits, Krisztian, Rastenyte, Daiva, Rauer, Sebastian, Reifschneider, Gerd, Rey, Roberto, Rizvi, Syed A, Robertson, Derrick, Rodriguez, Jose Martinez, Rog, David, Roshanisefat, Homayoun, Rowe, Vernon, Rozsa, Csilla, Rubin, Susan, Rusek, Stanislaw, Saccà, Francesco, Saida, Takahiko, Salgado, Antonio Vasco, Sanchez, Victoria Eugenia Fernandez, Sanders, Kalina, Satori, Maria, Sazonov, Denis V, Scarpini, Elio Angelo, Schlegel, Eugen, Schluep, Myriam, Schmidt, Stephan, Scholz, Erich, Schrijver, H M, Schwab, Matthias, Schwartz, Raymond, Scott, James, Selmaj, Krzysztof, Shafer, Stuart, Sharrack, Basil, Shchukin, Ivan A, Shimizu, Yuko, Shotekov, Penko, Siever, Arno, Sigel, Karl-Otto, Silliman, Scott, Simo, Magdolna, Simu, Mihaela, Sinay, Vladimiro, Siquier, Antonio Escartin, Siva, Aksel, Skoda, Ondrej, Solomon, Andrew, Stangel, Martin, Stefoski, Dusan, Steingo, Brian, Stolyarov, Igor D, Stourac, Pavel, Strassburger-Krogias, Katrin, Strauss, Erik, Stuve, Olaf, Tarnev, Ivaylo, Tavernarakis, Antonios, Tello, Cristina Ramo, Terzi, Murat, Ticha, Veronika, Ticmeanu, Marina, Tiel-Wilck, Klaus, Toomsoo, Toomas, Tubridy, Niall, Tullman, Mark J, Tumani, Hayrettin, Turcani, Peter, Turner, Ben, Uccelli, Antonio, Urtaza, Francisco Javier Olascoaga, Vachova, Marta, Valikovics, Attila, Walter, Silke, Van Wijmeersch, Bart, Vanopdenbosch, Ludo, Weber, Joerg R, Weiss, Sara, Weissert, Robert, Vermersch, Patrick, West, Timothy, Wiendl, Heinz, Wiertlewski, Sandrine, Wildemann, Brigitte, Willekens, Barbara, Visser, L H, Vorobeychik, Galina, Xu, Xianhao, Yamamura, Takashi, Yang, Yi N, Yelamos, Sergio Martinez, Yeung, Michael, Zacharias, Alan, Zelkowitz, Marvin, Zettl, Uwe, Zhang, Meini, Zhou, Hongyu, Zieman, Ulf, Ziemssen, Tjalf, Kappos, Ludwig, Bar-Or, Amit, Cree, Bruce A C, Fox, Robert J, Giovannoni, Gavin, Gold, Ralf, Arnold, Douglas L, Arnould, Sophie, Scherz, Tatiana, Wolf, Christian, Wallström, Erik, and Dahlke, Frank

Published
2018
Full Text
View/download PDF

19. Disziplinen und Ansätze

Author

Owen, Linda R., Schubert, Markus, Schröter, Susanne, Martschukat, Jürgen, Stieglitz, Olaf, Albrecht, Daniel, Spieß, Constanze, Stuve, Olaf, Groneberg, Michael, Mertens, Wolfgang, Brandes, Holger, Collier, Richard, Krondorfer, Björn, Meuser, Michael, Horlacher, Stefan, editor, Jansen, Bettina, editor, and Schwanebeck, Wieland, editor

Published
2016
Full Text
View/download PDF

22. Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis

Author

Spain, Rebecca I., primary, Hildebrand, Andrea, additional, Waslo, Carin S., additional, Rooney, William D., additional, Emmons, Joshua, additional, Schwartz, Daniel L., additional, Freedman, Mark S., additional, Paz Soldan, M. Mateo, additional, Repovic, Pavle, additional, Solomon, Andrew J., additional, Rinker, John, additional, Wallin, Mitchell, additional, Haselkorn, Jodie K., additional, Stuve, Olaf, additional, Gross, Robert H., additional, and Turner, Aaron P., additional

Published
2023
Full Text
View/download PDF

26. Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)

Author

Montalban, Xavier, Vermersch, Patrick, Arnold, Douglas L., Bar-Or, Amit, Cree, Bruce A.C., Cross, Anne, Havrdova, Eva Kubala, Kappos, Ludwig, Stuve, Olaf, Wiendl, Heinz, Wolinsky, Jerry, Bolay, Claire Le, Hyvert, Yann, Javor, Andrija, Guehring, Hans, Tenenbaum, Nadia, and Tomic, Davorka

Published
2023
Full Text
View/download PDF

30. sj-pdf-1-tan-10.1177_17562864231156674 – Supplemental material for Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease

Author

Stopschinski, Barbara E., Weideman, Rick A., McMahan, Danni, Jacob, David A., Little, Bertis B., Chiang, Hsueh-Sheng, Saez Calveras, Nil, and Stuve, Olaf

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-pdf-1-tan-10.1177_17562864231156674 for Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease by Barbara E. Stopschinski, Rick A. Weideman, Danni McMahan, David A. Jacob, Bertis B. Little, Hsueh-Sheng Chiang, Nil Saez Calveras and Olaf Stuve in Therapeutic Advances in Neurological Disorders

Published
2023
Full Text
View/download PDF

35. List of contributors

Author

Bagnato, Francesca, Barter, Kelsey, Benedict, Ralph H.B., Bergsland, Niels, Bsteh, Gabriel, Buch, Sagar, Calabrese, Massimiliano, Calveras, Nil Saez, Cercignani, Mara, Chandra, Avinash, Cho, Chloe, Cho, Junghun, Cicero, Steven, Dimov, Alexey, Dwyer, Michael G., Eckert, Svetlana, Fenu, Giuseppe, Haacke, E. Mark, Hansel, Caleb, Inojosa, Hernan, Jakimovski, Dejan, Koch, Carynn, Kolb, Channa, Krajnc, Nik, Krijnen, Eva A., Kuceyeski, Amy, Laganà, Maria Marcella, Laule, Cornelia, Lorefice, Lorena, Mancini, Matteo, McKnight, Colin, Pelizzari, Laura, Rauscher, Alexander, Rissanen, Eero, Rohm, Zachery, Schoonheim, Menno M., Schweser, Ferdinand, Singhal, Tarun, Stuve, Olaf, Tamanti, Agnese, Tavazzi, Eleonora, Tozlu, Ceren, Uher, Tomas, Vaneckova, Manuela, Vavasour, Irene M., Weinstock, Zachary L., Weinstock-Guttman, Bianca, Ziemssen, Tjalf, and Zivadinov, Robert

Published
2025
Full Text
View/download PDF

36. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

Author

D’Haens, Geert, Vermeire, Séverine, Vogelsang, Harald, Allez, Matthieu, Desreumaux, Pierre, Van Gossum, Andre, Sandborn, William J, Baumgart, Daniel C, Ransohoff, Richard M, Comer, Gail M, Ahmad, Alaa, Cataldi, Fabio, Cheng, John, Clare, Robert, Gorelick, Kenneth J, Kaminski, Annamarie, Pradhan, Vivek, Rivers, Sunday, Sikpi, Matthew O, Zhang, Yanhua, Hassan-Zahraee, Mina, Reinisch, Walter, and Stuve, Olaf

Published
2018
Full Text
View/download PDF

39. Cell-based therapeutic strategies for multiple sclerosis

Author

Scolding, Neil J, Pasquini, Marcelo, Reingold, Stephen C, Cohen, Jeffrey A, Atkins, Harold, Banwell, Brenda, Bar-Or, Amit, Bebo, Bruce, Bowen, James, Burt, Richard, Calabresi, Peter, Cohen, Jeffrey, Comi, Giancarlo, Connick, Peter, Cross, Anne, Cutter, Gary, Derfuss, Tobias, Ffrench-Constant, Charles, Freedman, Mark, Galipeau, Jacques, Goldman, Myla, Goldman, Steven, Goodman, Andrew, Green, Ari, Griffith, Linda, Hartung, Hans-Peter, Hemmer, Bernhard, Hyun, Insoo, Iacobaeus, Ellen, Inglese, Matilde, Jubelt, Burk, Karussis, Dimitrios, Küry, Patrick, Landsman, Douglas, Laule, Cornelia, Liblau, Roland, Mancardi, Giovanni, Ann Marrie, Ruth, Miller, Aaron, Miller, Robert, Miller, David, Mowry, Ellen, Muraro, Paolo, Nash, Richard, Ontaneda, Daniel, Pasquini, Marcelo, Pelletier, Daniel, Peruzzotti-Jametti, Luca, Pluchino, Stefano, Racke, Michael, Reingold, Stephen, Rice, Claire, Ringdén, Olle, Rovira, Alex, Saccardi, Riccardo, Sadiq, Saud, Sarantopoulos, Stefanie, Savitz, Sean, Scolding, Neil, Soelberg Sorensen, Per, Pia Sormani, Maria, Stuve, Olaf, Tesar, Paul, Thompson, Alan, Trojano, Maria, Uccelli, Antonio, Uitdehaag, Bernard, Utz, Ursula, Vukusic, Sandra, Waubant, Emmanuelle, and Wilkins, Alastair

Published
2017
Full Text
View/download PDF

41. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.

Author

Reder, Anthony T, Stuve, Olaf, Tankou, Stephanie K, and Leist, Thomas P

Subjects
*SARS-CoV-2, *PSYCHONEUROIMMUNOLOGY, *COVID-19 pandemic, *COVID-19, *T cells, *COVID-19 vaccines, *CORONAVIRUS diseases
Abstract

Background: Multiple sclerosis (MS) is a neurological disorder marked by accumulating immune-mediated damage to the central nervous system. The dysregulated immune system in MS combined with immune effects of disease-modifying therapies (DMTs) used in MS treatment could alter responses to infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). Most of the literature on immune response to SARS-CoV-2 infection and COVID-19 vaccination, in both the general population and patients with MS on DMTs, has focused on humoral immunity. However, immune response to COVID-19 involves multiple lines of defense, including T cells. Objective and Methods: We review innate and adaptive immunity to COVID-19 and expand on the role of T cells in mediating protective immunity against SARS-CoV-2 infection and in responses to COVID-19 vaccination in MS. Results: Innate, humoral, and T cell immune responses combat COVID-19 and generate protective immunity. Assays detecting cytokine expression by T cells show an association between SARS-CoV-2-specific T cell responses and milder/asymptomatic COVID-19 and protective immune memory. Conclusion: Studies of COVID-19 immunity in people with MS on DMTs should ideally include comprehensive assessment of innate, humoral, and T cell responses. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Treatment of neuromyelitis optica: Review and recommendations

Author

Kimbrough, Dorlan J., Fujihara, Kazuo, Jacob, Anu, Lana-Peixoto, Marco A., Isabel Leite, Maria, Levy, Michael, Marignier, Romain, Nakashima, Ichiro, Palace, Jacqueline, de Seze, Jérôme, Stuve, Olaf, Tenembaum, Silvia N., Traboulsee, Anthony, Waubant, Emmanuelle, Weinshenker, Brian G., and Wingerchuk, Dean M.

Published
2012
Full Text
View/download PDF

46. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure

Author

Manouchehri, Navid, Salinas, Victor H., Rabi Yeganeh, Negar, Pitt, David, Hussain, Rehana Z., and Stuve, Olaf

Subjects
Neurology, Neurology (clinical)
Abstract

The advent of disease modifying therapies (DMT) in the past two decades has been the cornerstone of successful clinical management of multiple sclerosis (MS). Despite the great strides made in reducing the relapse frequency and occurrence of new signal changes on neuroimaging in patients with relapsing remitting MS (RRMS) by approved DMT, it has been challenging to demonstrate their effectiveness in non-active secondary progressive MS (SPMS) and primary progressive MS (PPMS) disease phenotypes. The dichotomy of DMT effectiveness between RRMS and progressive MS informs on distinct pathogeneses of the different MS phenotypes. Conversely, factors that render patients with progressive MS resistant to therapy are not understood. Thus far, age has emerged as the main correlate of the transition from RRMS to SPMS. Whether it is aging and age-related factors or the underlying immune senescence that qualitatively alter immune responses as the disease transitions to SPMS, that diminish DMT effectiveness, or both, is currently not known. Here, we will discuss the role of immune senescence on different arms of the immune system, and how it may explain relative DMT resistance.

Published
2022
Full Text
View/download PDF

47. sj-docx-1-msj-10.1177_13524585221134216 – Supplemental material for T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Author

Reder, Anthony T, Stuve, Olaf, Tankou, Stephanie K, and Leist, Thomas P

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221134216 for T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy by Anthony T Reder, Olaf Stuve, Stephanie K Tankou and Thomas P Leist in Multiple Sclerosis Journal

Published
2022
Full Text
View/download PDF

49. Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.

Author

Shirani, Afsaneh, Cross, Anne H., and Stuve, Olaf

Subjects
ANTIOBESITY agents, DATABASES, DATA scrubbing, MULTIPLE sclerosis, NALTREXONE
Abstract

The authors of the article titled "Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database" respond to a comment made by Dr. Khouri et al. They clarify that they used the term "inverse association" rather than "inverse causality" to highlight potential relationships that require further investigation, and not to suggest direct protective effects. They acknowledge the limitations of using the FDA adverse event reporting system database and the need for additional sensitivity analyses and controls. The authors also agree that integrating other methodological approaches, such as omics and in vitro testing, can provide more comprehensive insights, but this was beyond the scope of their current report. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results